Business Standard

Dr Reddy's gains as USFDA completes inspection of Srikakulam SEZ unit

The stock was up 3% at Rs 2,712 against 0.18% decline in the S&P BSE Sensex at 09:30 am.

Dr Reddy's Q1 net down 76% at Rs 154 cr
Premium

SI Reporter Mumbai
Dr Reddy’s Laboratories was up 3% at Rs 2,722 on BSE in intra-day trade after the company on Friday announced that the US drug regulator has completed the audit of active pharmaceutical ingredients (APIs) manufacturing plant at Srikakulam special economic zone (SEZ) in Andhra Pradesh with no observations.

At 09:38 am; the stock was up 2.7% at Rs 2,712 against 0.18% decline in the S&P BSE Sensex. A combined 178,690 shares changed hands on the counter on BSE and NSE so far.

On March 22, 2017, the stock of Dr Reddy’s Laboratories hit an over two-year low of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in